SCHEMBL1184496

SCHEMBL1184496

CN1C(=O)CCC(=O)c2ccc(Cl)cc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 3/20 0.52
SRD5A2 P31213 1/20 0.52
OPRK1 P41145 2/20 0.44
PDE4D Q08499 1/20 0.44
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
TSPO P30536 1/20 0.43
KMT2A Q03164 1/20 0.42
GABRA1 P14867 3/20 0.42
GABRG2 P18507 3/20 0.42
GABRB3 P28472 3/20 0.42
GABRA5 P31644 3/20 0.42
GABRA3 P34903 3/20 0.42
GABRA2 P47869 3/20 0.42
GABRP O00591 2/20 0.42
GABRD O14764 2/20 0.42
GABRB1 P18505 2/20 0.42
GABRB2 P47870 2/20 0.42
GABRA4 P48169 2/20 0.42
GABRE P78334 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11263558 0.79 SRD5A1 (0.55) SRD5A1SRD5A2OPRK1PDE4DLMNA
SCHEMBL11255201 0.76 SRD5A1 (0.59) SRD5A1SRD5A2OPRK1PDE4DKMT2A
SCHEMBL14746122 0.75 NOTUM (0.42) SRD5A1SRD5A2LMNAGAAKMT2A
SCHEMBL1184701 0.75 KMT2A (0.56) OPRK1PDE4DKMT2A
SCHEMBL1184530 0.73 MAPT (0.43) SRD5A1SRD5A2OPRK1PDE4DLMNA
SCHEMBL1184633 0.73 MEN1 (0.61) LMNAGAAKMT2A
SCHEMBL1185490 0.72 MEN1 (0.45) LMNAKMT2A
SCHEMBL31536334 0.72 CES1 (0.55) KMT2ACA12CA2CA4CA7
SCHEMBL7780180 0.72 CES1 (0.55) KMT2ACA12CA2CA4CA7
SCHEMBL25557384 0.71 ALDH1A1 (0.53) LMNAGAAKMT2AADRA1BCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799684-B1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARM INC (US) 2014-12-03 EP disclosed
US-20120178739-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-07-12 US disclosed
US-7935694-B2 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-05-03 US disclosed
US-20110039820-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 US disclosed
US-20090105213-A1 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-04-23 US disclosed
US-7459448-B2 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
EP-1799684-A2 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-27 EP disclosed
US-20060100194-A1 Lactam compounds useful as protein kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. 2006-05-11 US disclosed
WO-2006041773-A2 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100194-A1 Lactam compounds useful as protein kinase inhibitors PRKCI, PIK3CA, AKT1 SRD5A1 3960/4885SRD5A2 4377/4885OPRK1 1535/4885
US-20120178739-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS PRKCI, PIK3CA, AKT1 SRD5A1 3960/4885SRD5A2 4377/4885OPRK1 1535/4885
US-20090105213-A1 Lactam compounds useful as protein kinase inhibitors PRKCI, PIK3CA, AKT1 SRD5A1 3960/4885SRD5A2 4377/4885OPRK1 1535/4885
US-20110039820-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS PRKCI, PIK3CA, AKT1 SRD5A1 3960/4885SRD5A2 4377/4885OPRK1 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.